Patient P-01590
Synthetic patientNBL-101 · Day 113 · 25–34 · F · baseline S19Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Improving
GI state
Favorable
Inflammatory state
Improving
Nutritional resilience
Favorable
Discontinuation risk
12%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S19
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- Toxicity-9
- Inflammatory activity-7
- GI instability-3
- Treatment adherence-2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion19.1/100
stable · -0.7 vs previous 14 d
Toxicity
Blood11.9/100
improving · -2.5 vs previous 14 d
Sleep quality
Wearable46.4/100
improving · +6.5 vs previous 14 d
Energy level
Daily log6.5/10
improving · +0.5 vs previous 14 d
Stress level
Daily log4.2/10
improving · -0.5 vs previous 14 d
Steps
Wearable7,524
stable · +230 vs previous 14 d
Adherence
Companion90.7 %
improving · +3.9 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 76 from the failing basin, 19 from restoration.
Good elements to keep
- Butyrate producers intacthidden · steering +7.5
- Daily walks resumedperturbation · steering +3.3
Main detractors to watch
- Poor metabolizerhidden · steering -12.7
- Bacteroides fragilis elevatedhidden · steering -7.4
- Antibiotic courseperturbation · steering -4.7
- Poor-sleep weekperturbation · steering -3
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Insoluble fibre+1no signal · 28%
- Alcohol+0.8no signal · 25%
- Spicy / capsaicin-0.7no signal · 21%
- Simple carbohydrates-0.6no signal · 18%
- Dietary fat load+0.5no signal · 15%
- Histamine load-0.4no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Drug metabolism and exposure ↑75
- DNACYP2D6 poor metabolizer → higher exposure
- DNADPYD *2A → slower clearance
- Inflammatory signalling ↓35
- MicrobiomeBacteroides fragilis expansion
- WearableHRV 34 ms, trending down
- Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
DNA
Fictional pharmacogenomic panel
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 3.8 · butyrate capacity 53/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 32 ms
- Sleep
- 7.9 h
- Steps
- 7,849
- Resting HR
- 68 bpm
Daily log: GI score 19, nutritional resilience 62, adherence 91.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.